Patients with operable breast cancer with 0 to 3 positive nodes were enrolled onto the study to address the noninferiority of single-agent T to AC , defined as the one-sided 95 % upper-bound CI ( UCB ) of hazard ratio ( HR ) of T versus AC less than 1.30 for the primary end point of relapse-free survival ( RFS ) .